PeptiDream Inc., PDRadiopharma Inc. — a wholly owned subsidiary of PeptiDream — and Curium Group, a global leader in nuclear medicine, have announced the initiation of a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a novel PET radiopharmaceutical…
Adagio Medical Holdings, Inc., a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, announced the pricing of a private placement of its securities with certain accredited investors. The offering is expected to generate approximately $19 million…
Eradivir Inc., a clinical-stage biotechnology company leveraging the immune system to treat infectious diseases, today announced the successful completion of its Phase 2a clinical trial evaluating EV25, a novel therapy for influenza. The trial demonstrated that EV25 is safe, well-tolerated,…
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the establishment of a global, cross-functional Scientific Advisory Board to guide the company’s strategic focus on New Approach Methodologies (NAMs). The Advisory Board, led by Dr. Namandjé N. Bumpus, will play…
Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on integrating advanced engineering with cutting-edge laboratory and in silico research to accelerate drug discovery, today announced that new data from its ongoing Phase 2 study of EIK1001 (TeLuRide-005) will be…
Augurex Life Sciences Corp., a leading innovator in autoimmune-based diagnostics, today announced a strategic agreement with MitogenDx, a Canadian specialty laboratory focused on autoimmune and rheumatology diagnostic testing. Under the terms of the agreement, MitogenDx will offer the JOINTstat® blood…
Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the successful close of a $120 million Series B financing, co-led by ARCH Venture Partners and GV (Google Ventures), with participation from existing investors including Main Street Advisors, Visionary Ventures,…
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, announced new data from the phase I CLARITY open-label crossover study, highlighting significant differences in injection site reaction (ISR) acceptability and overall tolerability between…
Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain associated with osteoarthritis (OA) in dogs. Lenivia represents a novel monoclonal antibody therapy, developed over a decade of rigorous scientific research, designed to…
MindWalk Holdings Corp.™, a Bio-Native AI company transforming life sciences data intelligence, today announced the appointment of industry veteran Thomas W. Lynch, Ph.D., as Chief Business Officer (CBO), effective October 20, 2025. This strategic hire is aimed at accelerating the…